| |
| POWERPOINT DOWNLOADS |
 |
| This program has taken place. The following Powerpoint files from the presenters are available for download. |
|
|
|
|
|
|
|
|
| PRIOR SYMPOSIA |
|
| Although the following symposia have already taken place, you can download Powerpoint files used by the presenters and find additional information about many of these events. |
|
| • |
BACK TO CURRENT |
|
| • |
New York, NY |
| |
10/30/2007 |
|
| • |
Los Angeles, CA |
| |
10/24/2007 |
|
| • |
San Francisco, CA |
| |
09/26/2007 |
|
| • |
New York, NY |
| |
03/21/2007 |
|
| • |
Washington, DC |
| |
11/08/2006 |
|
| • |
Los Angeles, CA |
| |
10/25/2006 |
|
| • |
New York, NY |
| |
03/15/2006 |
|
| • |
Los Angeles, CA |
| |
10/26/2005 |
|
| • |
Rochester, NY |
| |
10/18/2005 |
|
| • |
Portland, ME |
| |
10/05/2005 |
|
| • |
MORE... |
|
| |
|
|
|
|
|
|
|
|
|
|
 |
Wednesday, March 21, 2007
UPDATE ON THE MANAGEMENT OF HYPERTENSION
• Attendance is FREE!
The program will be of interest to family practitioners, internists, cardiologists, and other health care professionals.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
University Club
1 West 54th Street
New York, NY 10019
|
 |
Program: 12:00 PM – 4:45 PM
The club requires jackets and ties for gentlemen, and clothing of equal formality for the ladies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROGRAM |
|
| 12:00 PM |
Lunch and Registration
|
|
| 1:00 PM |
Introduction
Moser M |
|
| 1:05 PM |
VALUE, ASCOT, TROPHY and Other Acronyms: Should the Results of These Hypertension Trals Be Incorporated into Treatment Decisions?
Moser M |
|
| 1:50 PM |
Question & Answer
|
|
| 2:00 PM |
Is it Important To Diagnose the Metabolic Syndrome? How Do You Treat It?
Sowers JR |
|
| 2:30 PM |
Question & Answer
|
|
| 2:40 PM |
Break
|
|
| 2:55 PM |
Resistant Hypertension: What To Do?
Black HR |
|
| 3:40 PM |
Question & Answer
|
|
| 3:50 PM |
Participant and Audience Discussion
1. Home and Ambulatory Blood Pressures: Are They Helpful in Managing Patients?
2. More on Prehypertension: Should It Be Treated and How?
3. Is There Still a Role for Beta Blockers in the Management of Hypertension?
4. Is New Onset Diabetes of Clinical Significance?
|
|
| 4:45 PM |
Adjournment |
|
|
|
|
|
CHAIR
Marvin Moser, MD
Clinical Professor of Medicine
Yale University School of Medicine
New Haven, CT
President, Hypertension Education Foundation, Inc.
ADDITIONAL SPEAKERS
Henry R. Black, MD
Clinical Professor of Internal Medicine
New York University School of Medicine
New York, NY
James R. Sowers, MD
Professor of Medicine and Physiology
Director
Diabetes Research Center
University of Arizona Health Sciences
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
This program provides an opportunity to meet the experts and discuss evidence-based medicine as it relates to the clinical diagnosis, treatment, and management of hypertension.
SYPOSIUM OBJECTIVES
Upon completion of this program, attendees should be able to:
• Apply the results of recent hypertension trials to formulate treatment decisions
• Explain the cluster of risk factors that constitutes the metabolic syndrome
• Recognize the value of, and options for, treatment of the metabolic syndrome
• Identify resistant hypertension and explain the value of combination drug therapies in its treatment
• Critically evaluate the efficacy of home blood pressure measurement, the role of beta blockers in the management of hypertension, and the importance of the diagnosis and management of prehypertension
• Discuss the clinical significance of new onset diabetes
ACCREDITATION STATEMENT
The American Society of Hypertension, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
DESIGNATION STATEMENT
The American Society of Hypertension, Inc. designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Each physician should claim credit commensurate with the extent of their participation in the activity.
CME ACTIVITY
Sponsored by the American Society of Hypertension, Inc. in cooperation with the Hypertension Education Foundation, Inc. and The Journal of Clinical Hypertension. Funded by an educational grant from Novartis—its support is greatly appreciated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
